The RAS/RAF/MEK/ERK cell signaling pathway is a chain of proteins that carries signals from cell surface receptors to the DNA and is activated by a number of growth factors and cytokines through receptor tyrosine kinases.
ASCO has partnered with the College of American Pathologists, the American Society for Clinical Pathology, and the Association for Molecular Pathology, to create a guideline on the clinical utility of colorectal cancer biomarkers.
Wendy Kohlmann, Marjan Champine, and Dr. Sarah Colonna present their thoughts on discussing genetic testing with patients and their families, including obtaining informed consent, explanation of mutations, and recommendations for genetic counseling.
ASCO is planning to launch the Targeted Agent and Profiling Utilization Registry study to learn from observing the clinical practice of medicine using novel health information technology platforms, such as CancerLinQ™.
Diffuse large B-cell lymphoma has two distinct subtypes, activated B-cell and germinal center B-cell. Ongoing research seeks to develop assays to accurately determine DLBCL subtypes and find optimal therapies.
Numerous ongoing or planned clinical trials will help determine whether matching treatments to molecular or genomic profiles of patients actually results in improved outcomes. The Signature program has led to rapid start-up time for eight phase II trials testing targeted Novartis compounds.
Treatment with the Wee1 inhibitor AZD1775 plus carboplatin showed encouraging antitumor activity in patients with p53-mutated ovarian cancer that is refractory or resistant to standard first-line therapy.
Adoptive transfer of human leukocyte antigen partially matched Epstein Barr virus-specific cytotoxic T lymphocytes had limited toxicity and produced sustained responses after allogeneic hematopoietic or organ transplant.
Biomarkers suggestive of adaptive immune activity were seen in mRCC patients who had better clinical outcomes with nivolumab in a phase I trial. Upregulation of CTLA-4 and PD-L2 was seen during treatment with nivolumab, suggesting the potential for combination with ipilimumab in patients with mRCC.
One year of neratinib improved the rate of invasive disease-free survival compared to placebo in patients with HER2-positive early stage breast cancer who had undergone prior adjuvant therapy with chemotherapy and trastuzumab, according to results of a randomized phase III trial.